<DOC>
	<DOCNO>NCT02209779</DOCNO>
	<brief_summary>The objective determine effect BIRB 796 BS CRP clinical parameter Rheumatoid Arthritis measure efficacy , population pharmacokinetics safety parameter</brief_summary>
	<brief_title>Efficacy Safety Different Doses BIRB 796 BS Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female 18 75 year age Diagnosis Rheumatoid Arthritis ( RA ) establish accord ACR criterion date diagnosis &gt; 1 year ≤ 15 year . The exclusion patient disease duration &gt; 15 year delete Amendment 2 , effective January 22 , 2002 Patient belong functional class I , II , III Failure least one Disease Modifying Antirheumatic Drug ( DMARD ) due inefficacy Active disease , document visit 3 , define ≥10 swollen joint 66 joint count ≥ 12 tender joint 68 joint count CRP ≥ 2.0 mg/dl visit 1 visit 2 Written inform consent accordance Good Clinical Practice local legislation give prior study procedure , include washout prohibit medication Pregnancy ( exclude serum urine β Human ChorionGonadotropintest woman childbearing potential ) breast feed Female childbearing potential ( 6 month postmenopausal surgically sterilize ) use approve form birth control ( hormonal contraceptive , oral injectable/implantable , intrauterine device ( IUD ) ) Inflammatory rheumatic disease RA Active vasculitis history vasculitis ( characterised e.g . nail bed hemorrhage infarct , vasculitic purpura , ulcer gangrene , multisensory neuropathy , vasculitic retinopathy scleritis eye ) . Isolated rheumatoid nodule skin criterion exclusion Treatment failure TNFblocking agent . Treatment failure define achieve least ACR 20 response ( e.g . clinical trial ) clinical practice TNFblocking agent discontinue due ineffectiveness DMARD treatment within 4 week visit 3 Last dose give within specified time period visit 3 one follow compound drug : Infliximab ( Remicade® ) : 3 month D2E7 ( human TNFα antibody ) : 3 month Leflunomide ( Arava® ) : 1 year , exception patient undergone elimination therapy ( colestyramin 8 gram t.i.d . po eleven consecutive day ) , exclusion criterion delete Amendment 1 , effective September 3 , 2001 Drug classify proton pump inhibitor : 7 day Drug classify H2receptorblocker antacid : 2 day Investigational agent : 5fold respective plasma half life 4 week , whichever longer Treatment systemic corticosteroid dose high 10 mg/day prednisone equivalent within 4 week prior visit 3 Change treatment nonsteroidal antiinflammatory drug ( NSAIDs ) systemic corticosteroid within 4 week prior visit 3 Synovectomy , joint surgery , radio/chemo synoviorthesis steroid injection ( intraarticular , intravenous intramuscular ) within 4 week visit 3 Active infection serious infectious disease result hospitalisation require systemic antiinfective therapy within 4 week visit 3 Serologic evidence active hepatitis B and/or C Known HIVinfection History prior tuberculosis infection suspicion active infection screen base chest xray do within 6 month visit 1 History cardiovascular , renal , neurologic , psychiatric , liver , gastrointestinal , immunologic endocrine dysfunction clinically significant . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Recent history heart failure , define accord New York Heart Association criterion stage III IV ( i.e . three year less ) myocardial infarction ( i.e . one year less ) patient cardiac arrhythmia require drug therapy . This exclusion criterion slightly modify Amendment 2 , effective January 22 , 2002 . ECG result outside reference range clinical relevance include , limited QTcB &gt; 480 msec , PR interval &gt; 240 msec , QRS interval &gt; 110 msec History malignant disease last 5 year suspicion active malignant disease except successfully treat squamous basal cell carcinoma skin Clinically significant abnormal baseline hematology , blood chemistry urinalysis abnormality define disease list exclusion criterion Any follow specific laboratory abnormality : Alanine aminotransferase , aspartate aminotransferase , total bilirubin great upper limit normal ( ULN ) visit 1 measure within last six month visit 3 . This exclusion criterion modify Amendment 1 , effective September 3 , 2001 , allow retest Visit 2 . GammaGlutamyltransferase , alkaline phosphatase Lactate Dehydrogenase great 1.5 x ULN visit 1 creatinine white blood cell count great 1.5 x ULN visit 1 History drug alcohol abuse within past two year active drug alcohol abuse , present alcohol intake three drink per day Inability comply protocol Participation another clinical trial within 30 day visit 3 Previous enrolment trial Hypersensitivity trial drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>